XTL Biopharmaceuticals Ltd. ADR (XTLB)
NASDAQ: XTLBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
XTLB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.37M
- EPS (TTM)
- -$0.36
- Dividend yield
- None
- 52-week range
- 1.37 – 5.64
- Day range
- 1.37 – 1.59
- Volume / Avg
- 1.78K / 6.58K
- Beta
- —
- Shares outstanding
- 2.46M
52-week range
XTLB stock today
Shares of XTL Biopharmaceuticals (XTLB) finished lower on Nov 20 at $1.37, a drop of 5.84% or $0.085 per share, versus the S&P 500's 3.70% decline. Trading was light, with 1.78K shares changing hands, about 27% of the average daily volume. At this level, XTLB sits near the bottom of its 52-week range of $1.37 to $5.64: 75.7% below the high and 0.0% above the low.
XTL Biopharmaceuticals has posted a net loss over the last twelve months (EPS of -$0.36), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About XTL Biopharmaceuticals
Company profileXTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Noam Band
- Headquarters
- Herzliya, NY
- Employees
- 4
- Website
- xtlbio.com
Financial highlights
Full financialsIn fiscal 2024, XTL Biopharmaceuticals generated $451,000 in revenue. XTL Biopharmaceuticals reported a net loss of $1.0 million, compared with a loss of $1.8 million a year earlier. Gross margin was 0.7% and operating margin -481.6%.
| Fiscal year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Revenue | $451.00K | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-1.03M | $-1.78M | $-1.35M | $435.00K | $-2.95M |
| EPS (diluted) | $-0.003 | $-0.003 | $-0.002 | $0.00 | $-0.006 |
XTLB news
All XTLB newsXTL Biopharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| XBIOXenetic Biosciences Inc. | 1.40 | -9.09% | $3.28M | vs XTLB |
| IMNNImunon Inc. | 0.5355 | -5.22% | $3.47M | vs XTLB |
| APREAprea Therapeutics Inc. | 0.229 | -53.56% | $3.25M | vs XTLB |
| NRSNNeuroSense Therapeutics Ltd. | 1.28 | +1.59% | $3.19M | vs XTLB |
| KPRXKiora Pharmaceuticals Inc. | 0.7202 | -12.28% | $3.19M | vs XTLB |
| MDCXMedicus Pharma Ltd. | 1.14 | -2.16% | $3.16M | vs XTLB |
| AZTRAzitra Inc | 0.5168 | -2.75% | $3.13M | vs XTLB |
| NCNANuCana plc ADR | 0.7495 | +4.39% | $3.61M | vs XTLB |
Indexes, lists and sector
XTL Biopharmaceuticals stock FAQ
What is XTL Biopharmaceuticals's stock price today?
XTLB last traded at $1.37 as of Nov 20, 4:00 PM EST, down 5.84% on the day. Prices are delayed at least 15 minutes.
Who is XTL Biopharmaceuticals's CEO?
Mr. Noam Band is the chief executive officer of XTL Biopharmaceuticals Ltd. ADR, which has about 4 employees.
What is the XTLB 52-week high?
The 52-week high for XTLB is $5.64 and the 52-week low is $1.37. The stock is currently 75.7% below its high.